Lunit Company Description

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea.

It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer.

The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research; and with Summit Therapeutics Inc. to apply AI-powered SCOPE IO pathology platform for tumor microenvironment analysis in immuno-oncology development.

Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.

Lunit Inc.

Country	South Korea
Founded	2013
Industry	Medical - Healthcare Information Services
Sector	Healthcare
CEO	Beomseok Brandon Suh

Contact Details

Address: K-Square Gangnam 2 Seoul South Korea
Phone	82 2 2138 0827
Website	lunit.io

Stock Details

Ticker Symbol	328130
Exchange	KOSDAQ
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7328130000
SIC Code	7372

Key Executives

Name	Position
Beomseok Brandon Suh	Chief Executive Officer
Hyeonseong Park	Chief Financial Officer
Sunggyun Park	Chief Operating Officer